

Learning curve during percutaneous treatment of carotid lesions

MARCELO O. BETTINOTTI^{MTSAC, 1}, CARLOS SZTEJFMAN^{MTSAC, 1}, RAMÓN GOMES MARQUES¹, ALEJANDRO GOLDSMITH¹, FERNANDO CHIMINELLA¹, MATÍAS SZTEJFMAN¹, JOSÉ LUIS ROJAS¹, MARISA LEZCANO², JORGE HIRIART²

Received: 30/08/2011
Accepted: 22/03/2012

Address for reprints:

Dr. Marcelo O. Bettinotti
Sanatorio Güemes
Departamento de Hemodinamia
F. A. de Figueroa 1240
(1180) Ciudad Autónoma de Buenos Aires
e-mail:
marcelobettinotti@gmail.com

ABSTRACT

Background

Percutaneous transluminal angioplasty (PTA) of the carotid artery with stent implantation is an effective procedure for the prevention of ischemic stroke but its periprocedural morbimortality is still subject to debate.

Objective

The aim of this study is to report the results of a prospective series of patients treated with PTA.

Methods

This is a descriptive, observational, prospective study using the database of three Hemodynamic centers in Buenos Aires, which included all patients submitted to PTA from January 1998 to December 2010. The results of PTA performed by the same operator were analyzed.

Results

Mean age was 69 years, 58% of the patients were men, 58.8% were smokers, 52% had dyslipidemia, 79.1% were hypertensive, and 28% had diabetes. Prior history of acute myocardial infarction and coronary surgery was present in 19.4 and 11.6% of the patients, respectively. From 1998 to 2004 (initial stage, n=54) 72% of symptomatic patients had indication of revascularization, which was performed without cerebral protection in all cases. During the most recent stage (2004-2010, n=171), only 17.5% of the patients were symptomatic and revascularization was performed systematically with cerebral protection. Similar angiographic success was obtained in both stages (initial 96% vs. recent 97%), whereas clinical success rate was greater in the recent phase (96.1% vs. 87%, p=0.016). There were no cardiac complications. The rate of death or intrahospital stroke was 4%, 4.3% (3/70) in symptomatic and 3.2% (5/155) in asymptomatic patients; moreover, this rate was higher in the initial than in the recent phase (11.1% [6/54] vs. 1.7% [2/171], p=0.0028).

Conclusions

PTA represents an acceptably safe therapeutic alternative to surgical revascularization, providing the procedure is performed by experienced operators.

REV ARGENT CARDIOL 2012;80:287-292. <http://dx.doi.org/10.7775/rac.v80.i4.1352>

Key words > Carotid Stenosis - Carotid Angioplasty - Stroke

Abbreviations >

PTA	Percutaneous transluminal angioplasty	CP	Cerebral protection
CE	Carotid endarterectomy		

BACKGROUND

Stroke is the third cause of death in industrialized countries. Only in the United States 795000 cases of stroke are registered annually, presenting high mortality (17.6 %, n = 140.000) and frequently causing permanent physical disability. Extracranial athero-

sclerotic carotid artery lesions are responsible for at least 20 % of all stroke cases. (2) In the population over 65 years of age, the prevalence of at least 50 % carotid stenosis is 1 – 5 %. Historically, the existence of > 60% carotid stenosis in asymptomatic subjects is associated with a 5% 2-year risk of suffering ipsilat-

SEE RELATED ARTICLE: <http://dx.doi.org/10.7775/rac.v80.i4.1352> REV ARGENT CARDIOL 2012;80:269-70.

Sanatorio Güemes. Buenos Aires, Argentina
^{MTSAC} Full Member of the Argentine Society of Cardiology

¹ Department of Interventional Cardiology

² Department of Vascular Surgery

eral stroke, whereas in symptomatic subjects with > 70% stenotic lesion, the 2-year risk is 26%. (4, 5)

In a selected group of patients, carotid revascularization may provide an opportunity to reduce stroke risk. Several studies have shown carotid endarterectomy (CE) efficacy in the prevention of ischemic stroke in patients with $\geq 50\%$ lesions in symptomatic and with $\geq 80\%$ lesions in asymptomatic carotid stenosis, with perioperative morbimortality below 6% and 3%, respectively. (4-7) However, there is an increasing number of elderly patients with multiple comorbidities who despite the high surgical risk require revascularization

This has led to the development of other less invasive therapeutic alternatives, such as endovascular techniques. Carotid percutaneous transluminal angioplasty (PTA) and stenting under cerebral protection (CP) is the endovascular technique of choice for the treatment of carotid lesions. (2) Compared to balloon PTA, this technique has reduced re-intervention and distal embolization rate. (2)

In contrast with CE, PTA does not require general anaesthesia or neck incision, thus reducing recovery and hospitalization periods and, consequently the total costs of the intervention. Furthermore, it is not associated with peripheral neurological lesions as CE. Although the role of PTA is currently under revision, it represents a therapeutic option for patients with indication for carotid revascularization and CE contraindication. The purpose of this study is to report the results obtained in a prospective series of patients treated with PTA.

METHODS

This is a descriptive, observational, prospective study using the database of three Hemodynamic centers in Buenos Aires (Sanatorio Güemes, Instituto Médico de Alta Complejidad (IMAC), and Clínica Independencia).

All patients submitted to PTA from January 1998 to November 2010 were included in the study which was performed by the same operator in all cases. A written informed consent was obtained from each patient prior to the procedure. Patients with indication of carotid revascularization (asymptomatic with $\geq 80\%$ stenosis or symptomatic with $\geq 50\%$ lesion) presenting some of the following high risk variables were considered for PTA: 1) age > 75 years; 2) bilateral carotid disease; 3) contralateral occlusion; 4) ostial common carotid artery lesion or distal internal carotid artery lesion; 5) coronary disease associated with unstable angina; and 6) left ventricular ejection fraction < 35%.

As standard procedure, all patients were referred to clinical neurological evaluation and a carotid Doppler study prior to PTA. In patients with basal neurological deficits or periprocedural neurological symptoms, a control brain imaging study was performed (computed tomography or magnetic resonance imaging). Antiplatelet therapy consisted in periprocedural oral aspirin (325-100 mg given indefinitely) and clopidogrel (loading dose of 300 mg and maintenance dose of 75 mg) or ticlopidine (250 mg every 12 h) for 3 to 6 months. No sedation was used in order to preserve a constant neurological status in the patient. Both arterial pressure and O₂ saturation were monitored during

the procedure.

Intravenous heparin (70 mg/kg) was administered once the femoral artery was cannulated. In the majority of cases, the puncture site was the femoral artery; only in cases of bovine arch, the radial artery was used. In all cases, angiography of the carotid artery and both vertebral arteries was performed, including intracranial images, to assess collateral circulation in anteroposterior and lateral projections. At the end of the procedure, the same projections were used as comparative method.

In the first cases, the lesion was approached with a telescoping catheter. A 6 Fr JR 3 cm curve guide catheter (Medtronic, Minneapolis, Minnesota, USA) was used through an 8 Fr catheter (Cook Medical Inc., Bloomington, Indiana, USA). They were both advanced through a 0.035" \times 150 cm length hydrophilic wire (Glidewire Advantage™, Terumo Medical Corp., Tokyo, Japan), leaving the guide catheter just before the carotid bifurcation and removing the JR catheter and the hydrophilic wire to advance the CP device distally to the lesion. Afterwards, depending on the advance of lower profile CP systems, and also of carotid stents, use of the 7 Fr JR 3 cm curve guide catheter was implemented, positioning it in the proximal third of the common carotid artery to advance the CP filter and, according to the lesion, perform direct deployment of the self-expandable carotid stent or predilatation with a 4 mm diameter and 20 cm long balloon catheter followed by stent deployment.

According to the post-implant result, impact was performed with a 5 x 20 mm balloon at 6 atmospheres to retrieve the distal CP filter. It must be emphasized that in our department, CP device implantation started in 2004.

The endpoints were major cerebrovascular events (death, stroke) and transient ischemic attack during hospitalization. Preprocedural acute myocardial infarction was defined as anginal pain or its anginal equivalent, associated with enzymatic increase, with or without electrocardiographic alterations.

Angiographic success was considered when postprocedural stenosis was less than 30% by visual examination and clinical success as < 30% stenosis without major intrahospital complications (stroke, death, surgery or acute myocardial infarction).

Transient ischemic attack was defined as the neurologic event (hemispheric) with complete recovery within 24 hours of its occurrence. Stroke was defined as every neurological lesion (hemispheric) lasting more than 24 hours. All patients received systematic assessment during hospitalization by a neurologist belonging to the department. Clinical follow-up at 30 days was performed in 95% of the cases, either by phone call or by the patient's physician.

Statistics

Continuous variables are presented as mean \pm standard deviation. Categorical variables are expressed as percentages. Categorical variables were compared with the chi-square test or with Fisher's exact test, as appropriate.

Rate of angiographic and clinical success was compared according to the stage of the procedure (initial 1998-2003 vs. recent 2004-2010) and its symptomatic or asymptomatic classification. A p value < 0.05 was considered statistically significant. The statistical package SPSS 11.0 for Windows (SPSS Inc, Chicago, Ill, USA) was used for statistical analysis.

RESULTS

Two hundred and twenty five patients/232 carotid lesions were treated with PTA (Figure 1). Population

demographic characteristics are shown in Table 1. Thirteen percent of the patients were octogenarians, 42% were women and 28% were diabetic. More than a quarter of the patients (26.8%) had coronary disease and 11% had previous carotid revascularization. Thirty one percent of the patients had PTA indication due to ipsilateral neurological symptoms, 72% (29/54) in the initial stage and 17.5% (30/171; $p < 0.001$) in the recent stage.

Procedure characteristics are described in Table 2. Average basal stenosis was $84 \pm 11\%$ and 12,4% presented contralateral occlusion. Direct implantation was performed in 38.7% of the cases and postdilatation was frequent (see Table 2).

Angiographic and clinical success rates were 97% and 95.5%, respectively. Even though a similar angiographic success rate was obtained in both stages (initial 96% vs. recent 97%), the rate of clinical success in the recent stage was higher than that obtained in the initial stage (96.1% vs. 87%; $p = 0.016$).

One patient died due to a neurological event (hemorrhagic stroke) associated with the procedure and eight patients suffered stroke (7 ischemic and one hemorrhagic) between 24 and 72 hours after

the procedure (Table 3). Seven patients presented cerebral transient ischemic events manifested by dysarthria or brachial hemiparesis, recovering 20-30 minutes after the event; they all evidenced minimal or null intracranial collateral circulation and upon withdrawal of the protection filter this was seen to be occupied by atheromatous material. No other cardiological complications were observed (death or infarction).

The rate of intrahospital death or stroke was 4%, 4.3% (3/70) for symptomatic and 3.2% (5/155) for asymptomatic patients, while this rate was greater in the initial than in the recent stage [11.1% (6/54) vs. 1.7% (2/171); $p = 0.0028$]. No additional events were detected from discharge up to the 30 day follow-up.

DISCUSSION

In recent years, PTA has improved providing an alternative less invasive therapeutic approach to carotid obstruction. The adoption of this revascularization strategy was especially strengthened after the publication in 2002 of the SAPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy, $n=334$) study results. (8) This study compared CE vs. PTA with CP in symptomatic subjects with $>50\%$ carotid stenosis or asymptomatic subjects with $>80\%$ stenosis. The inclusion criteria required at least one risk factor for CE (age >80 , presence of heart failure, severe obstructive pulmonary disease, previous CE with re-stenosis, history of radiation or previous neck surgery, and very distal or proximal carotid lesions). The primary endpoint (stroke, death or infarction at 30 days or death/ipsilateral stroke at one




Fig. 1. Basal characteristics (n = 225)

Table 1. Basal characteristics (n = 225)

Age, years	69 ± 10
80 years of age, %	13,1
Men, %	58
Hypertension, %	79,1
Dyslipidemia, %	52
Diabetes, %	28
Smoking, %	50,8
Previous infarction, %	19,4
Previous coronary surgery, %	11,6
Previous carotid endarterectomy, %	9,4
Previous carotid angioplasty, %	6,5

Variables are expressed as mean \pm standard deviation or as percentage.

Table 2. Procedures (patients, n = 225; lesions, n = 232)

Left ICA, %	54,7
% basal stenosis	84 ± 11
Calcification, %	18,7
Ulceration, %	41,8
Contralateral occlusion, %	12,4
Employed Stents, %	
Wallstent	50
Precise	4
Protege	13
Smart	8
Others	25
Direct Stent, %	38,7
Postdilatation, %	71
Distal protection, %*	93,4
Angioguard	2,8
Emboshield	1,1
Epifilter	16,5
Filter Wire EZ	9,1
Spider	68,8
Others	1,7

ICA: Internal carotid artery. *Since 2004.

Table 3. Intra-hospital clinical results

	Total (n = 225)
Angiographic success, n (%)	219 (97,3)
Clinical success, n (%)	215 (95,5)
Neurological complications	
TIA, n (%)	7 (3,1)
Ischemic stroke, n (%)	7 (1,8)
Hemorrhagic stroke, n (%)	1 (0,04)
Access site complications	
Death	1 (0,04)

TIA: Transient ischemic attack.

year follow-up) was reached in 12.2% of the cases with PTA and in 20.1% with CE ($p = 0.004$), while peripheral neurological complication rate was 4.9% and 0% for CE and PTA, respectively. (8) These results led to the approval of PTA by the Food and Drug Administration (FDA) as an alternative treatment for patients at high surgical risk. Several subsequent multicentric studies, as ARChER (Acculink for Revascularization of Carotids in High Risk Patient), (9) SECURITY (Registry Study to Evaluate the Neuroshield Bare-Wire Cerebral Protection System and X-Act Stent in patients at high risk for Carotid Endarterectomy), CAPTURE (Carotid Acculink/Accunet Post-Approval Trial to Uncover Unanticipated or Rare Events) (10) and BEACH (Boston Scientific EPI: a carotid stenting trial for high-risk surgical patients) confirmed the safety and efficacy of PTA. (11)

More recently, the CREST study ($n = 2502$) compared both revascularization techniques in asymptomatic subjects with $\geq 60\%$ stenosis or symptomatic subjects with $\geq 50\%$ stenosis. (12) In this study, prior to participation eligibility, previous PTA training was requested from all operators, and use of only one PC system (Accunet®, Abbott, Santa Rosa, California, United States) was mandatory. (12) Although no differences were found in the primary endpoint (death, infarction or stroke at 30 days), the percutaneous treatment presented a higher composite rate of death or stroke at 30 days than the surgical treatment (4.4% vs. 2.3%; OR 1.90; 95% CI 1.21 to 2.98; $p < 0.005$), at the expense of a higher stroke rate in the symptomatic group (PTA 5.5% vs. CE 3.2%, $p = 0.043$). (12) On the other hand, the CE group exhibited higher risk of periprocedural acute myocardial infarction than the PTA group. Moreover, this study and others (13, 14) have reported a high risk of stroke or death in elderly patients submitted to PTA. However, this age group has also been shown to increase CE risk. In a Medicare report of 113300 patients submitted to CE in the United States, patients with ≥ 85 years presented a threefold higher risk of death than patients below 70 years of age. (15)

At present, there is no evidence of one carotid revascularization technique prevailing over the other in all clinical scenarios, except that both depend on

the characteristics of the patient or the lesion.

In our series of patients with carotid stenosis and other important surgical risk factors submitted to PTA, the composite event rate at 30 days (death and/or stroke) was 3.5%, 3.2% in asymptomatic patients and 4.2% in symptomatic patients. These results are favorable compared with those obtained in the CREST study (12) and they are also comparable to those reached in previous studies, such as SAPPHIRE and the global angioplasty registry (16) among others. Likewise, the results attained in our work are similar to the objectives postulated by the American Heart Association/American Stroke Association guidelines: $<6\%$ death or stroke risk in the symptomatic group and $<3\%$ in the asymptomatic group. (2)

As in the CREST study, our composite rate of periprocedural events was smaller after the exclusion of the initial stage cases, in which 72% of the patients were symptomatic and no CP was used.

Three randomized studies (SPACE, EVA 3S and ICSS) (17-19) only included symptomatic patients. Unlike SAPPHIRE and CREST, these studies reported a high rate of composite events with PTA, although they generated great controversy due to the presence of methodological errors which probably affected negatively the results of the percutaneous technique. In the SPACE study ($n=1200$), 73% of the percutaneous procedures were performed without CP. (18) Both techniques reported similar findings (stroke/death at 30 days: 6.84% and 6.34% for PTA and CE, respectively, $p= 0.09$ for noninferiority) although study enrolment was prematurely discontinued due to lack of funds. (18) On the other hand, in the EVA-3S study ($n = 527$), the operators had reduced PTA experience (the average PTA of included operators was 1.6 per year), and the study ended prematurely due to the high rate of events in the PTA group. (17) It is necessary to emphasize that in that study CP was not mandatory and 20% of the population did not receive double antiaggregant therapy. Furthermore, PTA without CP was associated with a higher rate of stroke at 30 days (25% vs. 7.9%, $p = 0.03$) compared to PTA with CP.

There is enough evidence in favor of the complementary use of both proximal (20) and distal (21) CP devices during PTA, and they are essential in symptomatic patients or patients with high risk of embolism. (22)

Several studies have revealed a close relationship between the amount of PTAs performed per institution or operator and the result of the procedure. (23-26) In the SAPPHIRE trial, the average operator experience was 64 cases (range 20 – 700) and similarly to surgeons, they had to have an acceptable rate of complications according to the American Heart Association criteria. (8) The need of adequate training and the mandatory use of CP systems are unquestionable in order to warrant acceptable and competitive results with respect to the surgical technique.

Therefore, several factors may have influenced the improvement observed in the rate of events during our recent stage a) a smaller proportion of symptomatic patients, b) greater experience resulting in better selection of patients and improved percutaneous technique, c) technological improvement of percutaneous instruments and CP adoption, d) implementation of advances in pharmacological treatment of carotid disease and secondary prevention. (27, 28)

However, this study has certain limitations that should be pointed out. This is an observational study, based on a relatively small sample, with a reduced follow-up period and without a comparative surgical group. Moreover, there are no available data on cognitive outcome of patients after the procedure.

Due to these limitations, we acknowledge that the present work does not define indisputable therapeutic conducts in patients with such a controversial pathology. However, this is a prospective series of high-risk patients treated with PTA by the same operator with acceptable results, where evident improvement in the outcome is revealed after following a learning curve.

CONCLUSIONS

Findings in the present study suggest that percutaneous treatment of carotid disease is a reasonably safe therapeutic technique, provided it is performed by skilled operators.

RESUMEN

Curva de aprendizaje en el tratamiento percutáneo de las lesiones carotídeas

Introducción

La angioplastia transluminal percutánea (ATP) carotídea con implante de stent es un procedimiento eficaz en la prevención del accidente cerebrovascular (ACV) de tipo isquémico, pero su morbimortalidad periprocedimiento aún es discutida.

Objetivo

Comunicar los resultados de una serie prospectiva de pacientes tratados con ATP.

Material y métodos

Estudio descriptivo, observacional y prospectivo de la base de datos de tres centros de Hemodinamia de la Ciudad de Buenos Aires, en el que se incluyeron todos los pacientes sometidos a ATP carotídea desde enero de 1998 a noviembre de 2010. Se analizaron los resultados de las ATP realizadas por un mismo operador.

Resultados

La edad media fue de 69 años, el 58% de los pacientes eran hombres, el 58,8% tabaquistas, el 52% dislipidémicos, el 79,1% hipertensos y el 28% diabéticos. El 19,4% y el 11,6% tenían historia previa de infarto y cirugía coronaria, respectivamente. Desde 1998 hasta 2004 (etapa inicial, n = 54) hubo un 72% de pacientes sintomáticos con indicación de revascularización; en esta etapa no se utilizó sistema de protección cerebral. En la etapa más contemporánea (2004-2010, n = 171), sólo el 17,5% fueron sintomáticos y el uso de sistema de protección cerebral fue sistemático. Se observó

una tasa similar de éxito angiográfico en las dos etapas (inicial 96% vs. contemporánea 97%), en tanto que la tasa de éxito clínico de la etapa contemporánea fue superior a la obtenida en la etapa inicial (96,1% vs. 87%; p = 0,016). No se observaron complicaciones cardiológicas. La tasa de muerte o ACV intrahospitalario fue del 4%, del 4,3% (3/70) en los sintomáticos y del 3,2% (5/155) en los asintomáticos; esta tasa fue mayor en la etapa inicial que en la contemporánea [11,1% (6/54) vs. 1,7% (2/171); p = 0,0028].

Conclusión

La ATP representa una alternativa terapéutica de aceptable seguridad, siempre que sea realizada por operadores experimentados.

Palabras clave > Estenosis carotídea - Angioplastia carotídea - Accidente cerebrovascular

REFERENCES

1. <http://www.strokecenter.org/patients/about-stroke-statistics/2011>.
2. Bates ER, Babb JD, Casey DE, Jr, Cates CU, Duckwiler GR, Feldman TE, et al. ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on carotid stenting. *Vasc Med* 2007;12:35-83.
3. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation* 2006;113:e873-923.
4. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA* 1995;273:1421-8.
5. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med* 1991;325:445-53.
6. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet* 1998;351:1379-87.
7. Chaturvedi S, Bruno A, Feasby T, Holloway R, Benavente O, Cohen SN, et al. Carotid endarterectomy an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2005;65:794-801.
8. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. *N Engl J Med* 2004;351:1493-501.
9. Gray WA, Hopkins LN, Yadav S, Davis T, Wholey M, Atkinson R, et al. Protected carotid stenting in high-surgical-risk patients: the ARCHEr results. *J Vasc Surg* 2006;44:258-68.
10. Gray WA, Yadav JS, Verta P, Scicli A, Fairman R, Wholey M, et al. The CAPTURE registry: results of carotid stenting with embolic protection in the post approval setting. *Catheter Cardiovasc Interv* 2007;69:341-8.
11. White CJ, Iyer SS, Hopkins LN, Katzen BT, Russell ME. Carotid stenting with distal protection in high surgical risk patients: the BEACH trial 30 day results. *Catheter Cardiovasc Interv* 2006;67:503-12.
12. Brott TG, Hobson RW 2nd, Howard G, Roubin GS, Clark WM, Brooks W, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. *N Engl J Med* 2010;363:11-23.
13. Chaturvedi S, Matsumura JS, Gray W, Xu C, Verta P. Carotid artery stenting in octogenarians: periprocedural stroke risk predictor analysis from the multicenter Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events (CAPTURE 2) clinical trial. *Stroke* 2010;41:757-64.
14. Voeks JH, Howard G, Roubin GS, Malas MB, Cohen DJ, Sternbergh WC 3rd, et al. Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. *Stroke* 2011;42:3484-90.

15. Wennberg DE, Lucas FL, Birkmeyer JD, Breidenberg CE, Fisher ES. Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. *JAMA* 1998;279:1278-81.
16. Wholey MH, Al-Mubarek N. Updated review of the global carotid artery stent registry. *Catheter Cardiovasc Interv* 2003;60:259-66.
17. Mas JL, Chatellier G, Beyssen B, Branchereau A, Moulin T, Becquemin JP, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. *N Engl J Med* 2006;355:1660-71.
18. Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke W, et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. *Lancet Neurol* 2008;7:893-902.
19. Ederle J, Dobson J, Featherstone RL, Bonati LH, van der Worp HB, de Borst GJ, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. *Lancet* 2010;375:985-97.
20. Ansel GM, Hopkins LN, Jaff MR, Rubino P, Bacharach JM, Scheinert D, et al. Safety and effectiveness of the INVATEC MO.MA proximal cerebral protection device during carotid artery stenting: results from the ARMOUR pivotal trial. *Catheter Cardiovasc Interv* 2010;76:1-8.
21. Matsumura JS, Gray W, Chaturvedi S, Gao X, Cheng J, Verta P. CAPTURE 2 risk-adjusted stroke outcome benchmarks for carotid artery stenting with distal embolic protection. *J Vasc Surg* 2010;52:576-83, 83e1-83e2.
22. Garg N, Karagiorgos N, Pisimisis GT, Sohal DP, Longo GM, Johanning JM, et al. Cerebral protection devices reduce periprocedural strokes during carotid angioplasty and stenting: a systematic review of the current literature. *J Endovasc Ther* 2009;16:412-27.
23. Smout J, Macdonald S, Weir G, Stansby G. Carotid artery stenting: relationship between experience and complication rate. *Int J Stroke* 2010;5:477-82.
24. Gray WA, Rosenfield KA, Jaff MR, Chaturvedi S, Peng L, Verta P. Influence of site and operator characteristics on carotid artery stent outcomes: analysis of the CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events) clinical study. *JACC Cardiovasc Interv* 2011;4:235-46.
25. Hopkins LN, Roubin GS, Chakhtoura EY, Gray WA, Ferguson RD, Katzen BT, et al. The Carotid Revascularization Endarterectomy versus Stenting Trial: credentialing of interventionalists and final results of lead-in phase. *J Stroke Cerebrovasc Dis* 2010;19:153-62.
26. Theiss W, Hermanek P, Mathias K, Bruckmann H, Dembski J, Hoffmann FJ, et al. Predictors of death and stroke after carotid angioplasty and stenting: a subgroup analysis of the Pro-CAS data. *Stroke* 2008;39:2325-30.
27. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342:145-53.
28. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;355:549-59.